The global Antibody Drug Conjugate (ADC) market is poised for significant growth, projected to expand from ADCs represent a breakthrough in targeted cancer therapy, combining the precision of monoclonal antibodies with the potency of cytotoxic drugs to selectively destroy cancer cells while minimizing harm to healthy tissues. This growth is fueled by rising cancer incidence worldwide,...

The Antibody-Drug Conjugates (ADC) market is experiencing significant growth, driven by the rising demand for targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. As of 2025, the global ADC market is valued at over USD 8 billion, with projections estimating it will surpass USD 20 billion by 2030, fueled by...